HARMONY BIOSCIENCES HOLDINGS (HRMY)
US4131971040 - Common Stock
Overall HRMY gets a fundamental rating of 7 out of 10. We evaluated HRMY against 193 industry peers in the Pharmaceuticals industry. HRMY gets an excellent profitability rating and is at the same time showing great financial health properties. HRMY has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings would make HRMY suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
HRMY had positive earnings in the past year.
HRMY had a positive operating cash flow in the past year.
In multiple years HRMY reported negative net income over the last 5 years.
In multiple years HRMY reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 13.21%, HRMY belongs to the top of the industry, outperforming 96.34% of the companies in the same industry.
The Return On Equity of HRMY (20.55%) is better than 92.67% of its industry peers.
The Return On Invested Capital of HRMY (18.64%) is better than 94.24% of its industry peers.
HRMY had an Average Return On Invested Capital over the past 3 years of 18.06%. This is significantly below the industry average of 43.18%.
The 3 year average ROIC (18.06%) for HRMY is below the current ROIC(18.64%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.21% | ||
| ROE | 20.55% | ||
| ROIC | 18.64% |
ROA(3y)16.93%
ROA(5y)-27.92%
ROE(3y)30.4%
ROE(5y)N/A
ROIC(3y)18.06%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of HRMY (17.98%) is better than 91.10% of its industry peers.
The Operating Margin of HRMY (28.21%) is better than 92.67% of its industry peers.
HRMY's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 78.65%, HRMY belongs to the best of the industry, outperforming 83.77% of the companies in the same industry.
HRMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.21% | ||
| PM (TTM) | 17.98% | ||
| GM | 78.65% |
OM growth 3Y46.09%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HRMY is creating value.
HRMY has less shares outstanding than it did 1 year ago.
The number of shares outstanding for HRMY has been reduced compared to 5 years ago.
HRMY has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.35 indicates that HRMY is not in any danger for bankruptcy at the moment.
HRMY has a better Altman-Z score (5.35) than 80.63% of its industry peers.
HRMY has a debt to FCF ratio of 0.83. This is a very positive value and a sign of high solvency as it would only need 0.83 years to pay back of all of its debts.
HRMY has a better Debt to FCF ratio (0.83) than 96.34% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that HRMY is not too dependend on debt financing.
HRMY has a Debt to Equity ratio (0.28) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 0.83 | ||
| Altman-Z | 5.35 |
ROIC/WACC1.91
WACC9.77%
2.3 Liquidity
A Current Ratio of 3.24 indicates that HRMY has no problem at all paying its short term obligations.
HRMY's Current ratio of 3.24 is in line compared to the rest of the industry. HRMY outperforms 52.36% of its industry peers.
A Quick Ratio of 3.20 indicates that HRMY has no problem at all paying its short term obligations.
HRMY has a Quick ratio (3.20) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.24 | ||
| Quick Ratio | 3.2 |
3. Growth
3.1 Past
The earnings per share for HRMY have decreased strongly by -23.55% in the last year.
HRMY shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.83%.
HRMY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 53.89% yearly.
EPS 1Y (TTM)-23.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.33%
Revenue 1Y (TTM)25.83%
Revenue growth 3Y53.89%
Revenue growth 5YN/A
Sales Q2Q%16.08%
3.2 Future
HRMY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.50% yearly.
The Revenue is expected to grow by 21.16% on average over the next years. This is a very strong growth
EPS Next Y-2.88%
EPS Next 2Y15.95%
EPS Next 3Y25.88%
EPS Next 5Y30.5%
Revenue Next Year22.25%
Revenue Next 2Y20.44%
Revenue Next 3Y21.16%
Revenue Next 5Y21.16%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 16.25, which indicates a correct valuation of HRMY.
Compared to the rest of the industry, the Price/Earnings ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 85.34% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.73. HRMY is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 10.54, the valuation of HRMY can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 86.91% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.83. HRMY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.25 | ||
| Fwd PE | 10.54 |
4.2 Price Multiples
90.05% of the companies in the same industry are more expensive than HRMY, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, HRMY is valued cheaper than 92.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.88 | ||
| EV/EBITDA | 7.87 |
4.3 Compensation for Growth
HRMY has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as HRMY's earnings are expected to grow with 25.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.95%
EPS Next 3Y25.88%
5. Dividend
5.1 Amount
No dividends for HRMY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HARMONY BIOSCIENCES HOLDINGS
NASDAQ:HRMY (12/20/2024, 8:17:07 PM)
After market: 34.28 0 (0%)34.28
+0.39 (+1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners72.67%
Inst Owner Change-1.39%
Ins Owners0.51%
Ins Owner Change-52.83%
Market Cap1.95B
Analysts77.33
Price Target48.05 (40.17%)
Short Float %14.13%
Short Ratio6.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)213.04%
Min EPS beat(2)16.47%
Max EPS beat(2)409.61%
EPS beat(4)3
Avg EPS beat(4)106.73%
Min EPS beat(4)-7.85%
Max EPS beat(4)409.61%
EPS beat(8)6
Avg EPS beat(8)62.25%
EPS beat(12)9
Avg EPS beat(12)125.88%
EPS beat(16)12
Avg EPS beat(16)190.97%
Revenue beat(2)0
Avg Revenue beat(2)-1.35%
Min Revenue beat(2)-1.8%
Max Revenue beat(2)-0.91%
Revenue beat(4)0
Avg Revenue beat(4)-1.67%
Min Revenue beat(4)-2.34%
Max Revenue beat(4)-0.91%
Revenue beat(8)2
Avg Revenue beat(8)-1.13%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)0.22%
PT rev (1m)6.77%
PT rev (3m)8.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.4%
EPS NY rev (1m)0.24%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)0.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.25 | ||
| Fwd PE | 10.54 | ||
| P/S | 2.87 | ||
| P/FCF | 8.88 | ||
| P/OCF | 8.85 | ||
| P/B | 3.28 | ||
| P/tB | 4.09 | ||
| EV/EBITDA | 7.87 |
EPS(TTM)2.11
EY6.16%
EPS(NY)3.25
Fwd EY9.49%
FCF(TTM)3.86
FCFY11.26%
OCF(TTM)3.87
OCFY11.3%
SpS11.96
BVpS10.46
TBVpS8.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.21% | ||
| ROE | 20.55% | ||
| ROCE | 25.09% | ||
| ROIC | 18.64% | ||
| ROICexc | 40.12% | ||
| ROICexgc | 60.28% | ||
| OM | 28.21% | ||
| PM (TTM) | 17.98% | ||
| GM | 78.65% | ||
| FCFM | 32.29% |
ROA(3y)16.93%
ROA(5y)-27.92%
ROE(3y)30.4%
ROE(5y)N/A
ROIC(3y)18.06%
ROIC(5y)N/A
ROICexc(3y)42.04%
ROICexc(5y)N/A
ROICexgc(3y)1605.28%
ROICexgc(5y)N/A
ROCE(3y)24.3%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y35.21%
ROICexc growth 5YN/A
OM growth 3Y46.09%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.43%
GM growth 5YN/A
F-Score6
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 0.83 | ||
| Debt/EBITDA | 0.77 | ||
| Cap/Depr | 3.11% | ||
| Cap/Sales | 0.11% | ||
| Interest Coverage | 10.98 | ||
| Cash Conversion | 102.01% | ||
| Profit Quality | 179.57% | ||
| Current Ratio | 3.24 | ||
| Quick Ratio | 3.2 | ||
| Altman-Z | 5.35 |
F-Score6
WACC9.77%
ROIC/WACC1.91
Cap/Depr(3y)235.53%
Cap/Depr(5y)610.69%
Cap/Sales(3y)14.03%
Cap/Sales(5y)258.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.33%
EPS Next Y-2.88%
EPS Next 2Y15.95%
EPS Next 3Y25.88%
EPS Next 5Y30.5%
Revenue 1Y (TTM)25.83%
Revenue growth 3Y53.89%
Revenue growth 5YN/A
Sales Q2Q%16.08%
Revenue Next Year22.25%
Revenue Next 2Y20.44%
Revenue Next 3Y21.16%
Revenue Next 5Y21.16%
EBIT growth 1Y-3.52%
EBIT growth 3Y124.82%
EBIT growth 5YN/A
EBIT Next Year21.54%
EBIT Next 3Y26.28%
EBIT Next 5Y26.29%
FCF growth 1Y91.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.18%
OCF growth 3YN/A
OCF growth 5YN/A